OBJECTIVE To conduct a comprehensive clinical evaluation of recombinant human growth hormone(rhGH) preparations, in order to evidence for the selection of medications in medical institutions and to promote rational clinical use.

METHODS Based on the evaluation framework of A Quick Guide to Drug Evaluation and Selection in Chinese Medical Institutions(the Second Edition), rhGH products were quantitatively assessed across 5 dimensions: pharmaceutical properties, efficacy, safety, economy, and other attributes. And evaluate based on the total scores.

RESULTS  The scoring results were as follows: the innovator drug Norditropin scored 74.9 points; the long-acting formulation Jintropin AQ scored 71.2 points; Saizeng liquid and powder scored 66.8 and 63.3 points, respectively; Genheal liquid and powder both scored 61.5 points; and Ansomone powder and liquid scored 61.4 and 60.2 points, respectively. According to the selection guidelines, all of the above rhGH were recommendable options, each possessing distinct characteristics and applicable scopes in clinical practice.

CONCLUSION The innovator and long-acting growth hormones have high comprehensive scores, but their prices are also relatively high. It is recommended to reduce prices and improve accessibility through methods such as including them in the medical insurance catalog via medical insurance negotiations and participating in national centralized drug procurement.For patients with limited financial means, domestic short-acting rhGH preparations represent an economical and effective treatment option.